Abstract: Renier Brentjens, MD, PhD, a pioneer of chimeric antigen receptor (CAR) T-cell therapy, speaks about his early work in the field, the current limitations of CAR T cells, and how researchers might advance the technology in the coming years.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: